Next Article in Journal
Recent Progress in Type I Aggregation-Induced Emission Photosensitizers for Photodynamic Therapy
Previous Article in Journal
The Bio-Patina on a Hypogeum Wall of the Matera-Sassi Rupestrian Church “San Pietro Barisano” before and after Treatment with Glycoalkaloids
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 1
10.3390/molecules28010331
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Research Progress of H2S Donors Conjugate Drugs Based on ADTOH

by
Shuai Wen
,
Changchang Cao
,
Jianwen Ge
,
Wenzhe Yang
,
Yan Wang
and
Yi Mou
*
College of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou 225300, China
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(1), 331; https://doi.org/10.3390/molecules28010331
Submission received: 25 October 2022 / Revised: 11 December 2022 / Accepted: 22 December 2022 / Published: 31 December 2022
Browse Figures
Versions Notes

Abstract

:
H2S is an endogenous gas signaling molecule and its multiple biological effects have been demonstrated. The abnormal level of H2S is closely related to the occurrence and development of many diseases, and H2S donors has important pharmacological implications. In recent years, H2S donors represented by ADTOH (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione) are often used to synthesize new ‘conjugate’ compounds that can release H2S and parent drugs. These hybrids retain the pharmacological activity of the parent drugs and H2S and have a synergistic effect. ADTOH and parent drug hybrids have become one of the important strategies for the development of H2S donor conjugate drugs. This review summarizes molecular hybrids between ADTOH and clinical drugs to provide new ideas for the study of H2S donor drug design.

1. H2S and H2S Donors

Hydrogen sulfide (H2S) is the third endogenous gas signaling molecule discovered after nitric oxide (NO) and carbon monoxide (CO). H2S plays an important regulatory role in a variety of physiological and pathological processes [1,2,3]. The reduction of H2S level in the body would lead to the occurrence and development of hypertension, atherosclerosis, gastrointestinal ulcer, liver cirrhosis, diabetes, inflammation, Alzheimer’s disease, cancer, and other diseases. Therefore, the supply of exogenous H2S is an effective way to solve the above questions [4,5,6,7,8,9]. However, the toxicological concentration of H2S is close to the physiological and pharmacological effective concentration, and the gas is volatile. Considering that, it is difficult to accurately control its effective concentration in vivo, which greatly limits the application of H2S gas itself as a drug in basic research and clinical trials. Therefore, sustained-release and controllable H2S donor drugs have not only broad application prospects, but also important significance for further elucidating the biological effect of H2S [10].
Like other gas signaling molecules, the activity of H2S is closely related to the site, concentration, and velocity of its release [11]. Therefore, the key problem in the study of H2S donor drugs is how to improve the selectivity of H2S donor molecules, release appropriate concentrations of H2S at the target site (generally the lesion site), play a therapeutic role while limiting its adverse reactions. At present, H2S donor can be roughly divided into sulfide salt, natural organic sulfur compounds, and synthetic H2S donors. Among them, many researchers focused on synthetic H2S donors. According to the different molecular structures and functional group properties, they can be broadly classified into thiophosphate derivatives (GYY4137) [12], aryl thiamides (TBZ) [13], 1,2-dithiole-3-thiones (ADT-OH) [14,15], thiol-activated H2S donors (NSHDs) [16], etc. (Figure 1).

2. ADTOH and Its Conjugates

5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADTOH) is the main metabolite of 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (ADT). The thione of ADTOH can be transformed into the corresponding ketone by hydrolysis and release H2S (Figure 2) [17]. In recent years, the research on ADTOH has been boosting. New H2S donor derivatives represented by ADTOH have been developed and designed widely, especially in some basic experimental studies. ADTOH is often used to synthesize new ‘conjugate’ compounds that can release H2S and parent drugs. Therefore, this paper reviews the hybrid compounds of ADTOH and parent drugs in order to provide a reference for the study of ADTOH-based donor drug design.

2.1. ADTOH–NSAID Conjugates

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used drugs. NSAIDs generate anti-inflammatory activities by inhibiting cyclooxygenase to reduce the production of inflammatory cytokines such as prostaglandins. However, long-term use of NSAIDs may lead to significant side effects, such as gastrointestinal adverse effects. It has been reported that NO and H2S could enhance the local defense of gastric mucosa, thus reducing NSAID-induced gastrointestinal disorders and other side effects [18,19]. Therefore, designing hybrids of H2S donors or NO donors together with NSAIDs to enhance the efficacy and reduce the side effects of NSAIDs is an important strategy of current research.
In recent years, new hybrid compounds linking ADTOH with NSAIDs are the most widely studied category in H2S research. These ADTOH–NSAID hybrids can release H2S and exert H2S activity while exerting the pharmacological effects of NSAIDs. The biggest advantage of these compounds compared with the parent NSAIDs is alleviating the gastrointestinal adverse effects.
NOSH-aspirin is a derivative formed by combining aspirin with ADTOH and NO donors (Figure 3). It has similar antipyretic, analgesic, anti-inflammatory and anti-platelet aggregation effects as aspirin, but has less adverse effects on gastrointestinal bleeding and better tumor prevention effects. In addition, HS-aspirin, a hybrid of aspirin and ADTOH exhibited inhibitory effects in estrogen receptor-negative breast cancer cells and leukemic Jurkat cells [20,21].
ATB-429 is a hybrid of mesalamine and ADTOH, which has improved anti-inflammatory and analgesic activity (Figure 4). ATB-429 significantly reduced gastrointestinal side effects compared to mesalamine, especially in a mouse model of colitis with better anti-inflammatory activity. ATB-429 exerts anti-inflammatory effects in LPS-induced liver injury, lung injury, ulcerative colitis. Additionally, it has anti-inflammatory effects in NSAID-induced gastric mucosal injury. ATB-429 is superior to mesalamine in reducing mucosal damage and disease severity; moreover, it significantly reduces the infiltration of chronic granulocytes and the expression of several important inflammatory cytokines mRNA. ATB-429 has entered Phase III clinical trials with the U.S. FDA [22]. Inspired by the above findings, Wang et al. [23] designed and synthesized a series of ATB-429 derivatives containing NO-releasing moieties, and evaluated its anti-tumor activity. The results showed that the derivatives have strong anti-tumor activity. Among them, compound 1a (IC50 = 2.677 µM), 1b (IC50 = 3.051 µM) against MCF-7 cancer cell line and 1a (IC50 = 1.270 µM) against DU145 cancer cell line are more active than Vandetanib (IC50 = 3.536, 1.974 µM).
ACS15 is an H2S donor-type derivative formed by the combination of diclofenac and ADTOH (Figure 5). Compared with diclofenac, it has better anti-inflammatory effects and less gastrointestinal adverse effects. ACS15 can release H2S in vitro and in vivo, thus not only improving anti-inflammatory activity, but also significantly reducing the lung injury associated with pancreatitis [24]. Another study found that ACS 15 had anti-myocardial ischemia reperfusion injury activity, while diclofenac did not show this activity [25].
ATB-352 is an H2S donor derivative obtained by the coupling of ketoprofen and ADTOH (Figure 5). Studies demonstrated that ATB-352 not only showed anti-inflammatory activity similar to ketoprofen, but also had almost no side effects on the gastrointestinal tract. It can be used for chemoprevention of tumors [26].
AVT-219 and AVT-18A (Figure 6) are NOSH drug complexes formed by combining naproxen and sulindac with ADTOH and NO donors [27]. Both AVT-219 and AVT-18A maintain the anti-inflammatory and anti-platelet aggregation properties of naproxen and sulindac. However, the side effect of naproxen and sulindac on the gastrointestinal tract is reduced. These NOSH compounds also have the ability to inhibit the growth activity of many tumor cells, including colon cancer cells, breast cancer cells, and pancreatic cancer cells [28].

2.2. ADTOH–Butylphthalide Conjugates

Despite the wide range of drugs available for the clinical management of ischemic stroke, none have yet achieved satisfactory results in the treatment of ischemic stroke. Blocking multiple components of the pathophysiological development of cerebral ischemia is the key to treating this type of disease. For ischemic stroke, the appropriate amount of exogenous NO and H2S supplementation can relax blood vessels, inhibit platelet aggregation, increase cerebral blood flow, and protect neuronal cells. On the other hand, supplementation of NO and H2S can inhibit the expression of iNOS, which is beneficial for the prevention and treatment of ischaemic brain injury diseases. Therefore, research on NO and H2S donor in anti-ischemic brain injury is a hot topic of current research [29,30].
Butylphthalide (NBP) is an effective stroke prevention drug. It inhibits platelet aggregation and reduces thrombosis and cerebral infarct volume. NBP can act on multiple pathological aspects of acute ischemic stroke through multiple targets, pathways, and links, and its clinical effects have been confirmed; however, it still has many shortcomings and needs to be developed further [31,32].
Wang et al. [33] synthesized a series of hydrogen sulfide-releasing derivatives by collocating butylphthalide with ADTOH and performed a biological evaluation of them (Figure 7). In vitro experiments, compound 2e significantly inhibited adenosine diphosphate (ADP) and arachidonic acid (AA)-induced platelet aggregation, with better effects than NBP, ticlopidine hydrochloride and aspirin. In addition, 2e produces moderate levels of H2S slowly in vitro, which is beneficial for improving cardiovascular circulation. On top of that, 2e has a protective effect on collagen and epinephrine-induced thrombosis in mice and exhibits stronger antithrombotic activity than NBP and aspirin in rats. In conclusion, 2e has promising applications in the treatment of thrombosis-related ischemic strokes.
Inspired by the above findings, Wang et al. [34] designed and synthesized a series of ADTOH-butylphthalide derivatives (Figure 7) by combining the ring-opening derivative of butylphthalein with ADTOH. Among them, compound 3e showed significantly better inhibitory activity than butylphthalide against platelet aggregation induced by adenosine diphosphate and arachidonic acid.
Additionally, Wang et al. [35,36] also synthesized a series of new NOSH-type compounds by combining butylphthalide with NO donors and ADTOH (Figure 8). Compared to butylphthalide parent, compound NOSH-NBP-5 has stronger anti-platelet aggregation activity and is capable of releasing both NO and H2S, exerting a protective effect on cardiovascular and cerebral circulation.

2.3. ADTOH–Niacin Conjugates

Niacin is known to be involved in lipid metabolism in the body, reducing plasma triglyceride and very low-density lipoprotein concentrations and increasing high density lipoprotein levels [37]. In addition, niacin has a vasodilating effect and is therefore commonly used clinically to treat hyperlipidemia, headaches, venous migraines, and cerebral artery thrombosis. Recent studies have shown that niacin can act as a neuroprotective agent in the treatment of stroke [38]. Therefore, the development of H2S donor-nicotinic acid hybrids designed to exert a synergistic neuroprotective effect is considered as a potential therapeutic strategy for ischemic brain injury.
Sun et al. [39] synthesized a range of derivatives by combining nicotinic acid with ADTOH. Most of the compounds were found to exhibit significant neuroprotective effects. Among them, compound 4f (Figure 9) can significantly reduce the volume of cerebral infarction in the pMCAO model. The results suggest that such compounds have promising applications in the interventional treatment of cerebral ischemic injury.

2.4. ADTOH–Levodopa Conjugates

Levodopa (L-DOPA) is currently an important drug in the treatment of Parkinson’s syndrome, but it only replenishes dopamine levels in the brain and does not inhibit the progression of the disease. Lee et al. [14] have combined L-DOPA with ADTOH to obtain a series of H2S-releasing derivatives (compounds ACS83 to ACS86, Figure 10). These derivatives not only can release dopamine but also protect nerves, and have antioxidant effects. Research has shown that ACS84 can avoid β-amyloid-induced neuronal cell damage through anti-inflammatory effects, and protect mitochondrial in p38- and JNK-mediated stress responses. Thus, ACS84 has the potential to treat neurodegenerative diseases [40].

2.5. ADTOH–Doxorubicin Conjugates

Doxorubicin is one of the most clinically effective antitumor agents, but cardiotoxicity and drug resistance limit its clinical use. In order to design doxorubicin derivatives with low cardiotoxicity and resistance, Chegaev et al. [41] used doxorubicin as a parent for conjugating with different hydrogen sulfide donors to obtain a series of compounds that can release hydrogen sulfide (compound 5b and 5d, Figure 11). It was found that all of these compounds reduced oxidative stress in cardiomyocytes, and some of them showed stronger activity in sarcoma cell lines. Unlike doxorubicin, most of the products are non-toxic to H9c2 cells at 5 μM concentration and have potential for further research and development.

2.6. ADTOH–Latanoprost Conjugate

Latanoprost (Xalatan) is an inactive but rapidly penetrating substance in the cornea, which can be hydrolyzed to active free acid in the cornea and plasma, increasing the outflow of atrial water through the corneal layer and having a good IOP lowering effect. Perrino et al. [42] designed and synthesized a hybrid (ACS 67, Figure 12) by combining latanoprost acid with ADTOH. Experimental data showed that this compound could increase the production of glutathione in the atrial fluid of rabbit eyes, antagonize the oxidative damage of hydrogen peroxide on the neuronal cells in the fundus, and thus alleviate the retinal ischemic damage, with significant optic neuroprotective effect. It has a significant effect on the treatment of glaucoma [43]. In addition, it has been found that ACS67 can inhibit L-type Ca2+ channels and reduce L-type voltage-dependent Ca2+ channel currents in pancreatic β-cells, thereby inhibiting insulin secretion, but the inhibitory effect is lower than that of NaHS [44].

2.7. ADTOH–Monastrol Conjugate

Monastrol, a mitotic kinesin inhibitor with potent and cell-permeable properties, was reported as an anti-cancer inhibitor back in the 1990s. Recent studies have shown that monastrol also has calcium channel blocker effects. Considering that H2S also has some calcium channel blocking effect, Braga et al. [45] designed and synthesized a Monastrol–ADTOH hybrid (MADTOH, Figure 13) using a conjugate strategy. Compared to monastrol, this compound was effective in reducing the overall calcium transient amplitude in cardiac myocytes via L-type calcium channels. Most notably, the intermediates ADTOH and monastrol were less effective than the hybrid MADTOH in controlling Ca2+ homeostasis. Overall, ADTOH hybridized with calcium channel blockers has a wide range of applications in the discovery of suitable calcium channel blockers.

2.8. ADTOH–Proglumide Conjugate

Atherosclerosis is a common cardiovascular disease. H2S has important physiological functions in atherosclerotic lesions, and many H2S donors have been synthesized to study atherosclerosis diseases. Proglumide can reduce the release of cytokines and inflammatory mediators in acute pancreatitis by inhibiting the activation of the NF-кB pathway. Considering that one of the etiologies of atherosclerotic disease is related to inflammation, Ou et al. [46] combined Proglumide with ADTOH to create a hybrid PA (Figure 14). Studies demonstrated that PA is a novel slow-releasing H2S donor and shows anti-atherosclerotic effect on the HUVECs injured model by inhibiting the activation of JAK/STAT pathway and NF-кb pathway.

2.9. ADTOH–Sildenafil Conjugate

Sildenafil is a drug that treats erectile dysfunction and pulmonary arterial hypertension. Muzaffar et al. used sildenafil as the parent and ADTOH to form the derivative ACS6 (Figure 15) and showed that ACS6 could enhance the efficacy by slowly releasing hydrogen sulfide, and its diastolic effect on spongy smooth muscle was much stronger than that of the parent drug sildenafil [47] and comparable to sildenafil citrate. Both inhibited oxygen radical generation in pulmonary artery endothelial cells compared with NaHS solution, but the effect was stronger than that of NaHS solution. Moreover, NaHS acts through the cAMP/PKA pathway, and ACS6 activates both the cAMP/PKA and cGMP/PKG pathways. It was also found that ACS 6 protects PC12 cells by upregulating paraoxonase-1 (PON-1) levels, which exerts anti-Hcy-induced neurotoxic and anti-oxidative stress effects [48,49].

2.10. ADTOH–Glucocorticoids Conjugates

Asthma is a heterogeneous clinical syndrome. Glucocorticoids are the most effective drugs for treating inflammation in asthma patients. Recent studies have shown that H2S has positive effect on this disease. Considering that an improved pharmacological activity and a reduced toxicity can be obtained through hybridization, Giordano et al. [50] designed and synthesized novel betamethasone and triamcinolone hybrids with H2S -donors (Figure 16). These synthesized compounds have potential H2S-releasing characteristics both in a cell-free environment and into the cytosol of BSMCs (bronchial smooth muscle cells). Among them, the most promising derivatives 6b and 6f have significant inhibitory effect on mast cell degranulation, resulting in a reduction of β-hexosaminidase release more efficiently than the corresponding parent drugs.
Additionally, Corvino et al. [51] also synthesized a series of novel prednisone and dexamethasone hybrids with two H2S -donors (Figure 17). The chemical stability of the synthesized hybrids has been investigated at differing pH values and in human serum. The results show that these hybrids have a prolonged chemical stability both at acidic and physiological pH. Among them, compound 7c was more effective than prednisone in inhibiting mast cell degranulation and in promoting BSMCs membrane hyperpolarization. Due to the protective effect on airway remodeling, compound 7c can be a potentially useful therapeutic option for allergic asthma treatment.
Compound 8, a hybrid of dexamethasone and H2S -donor moietie [52], is used to treat ocular diseases (Figure 18). Compound 8 has the ability to completely inhibit oxidative stress-induced glutathione depletion. This design not only eliminated the side effects associated with the parent compound, but also improved pharmacological effects.

2.11. ADTOH–Atorvastatin Conjugates

Atorvastatin is an HMG-CoA reductase inhibitor that reduces plasma cholesterol and lipoprotein levels. Tong et al. [53] designed and synthesized a series of atorvastatin–ADTOH hybrids (Figure 19). Compared with the parent drug atorvastatin, these compounds showed good activity of regulating blood lipids and anti-inflammatory and antioxidant properties. The results showed that these compounds have high application value in regulating blood lipids and vascular protection.

2.12. ADTOH–Pentacyclic Triterpene Conjugates

Oleanolic acid, ursolic acid, and glycyrrhetinic acid are the active ingredients of herbal medicines, belonging to pentacyclic triterpenes, which have been deeply researched for their various biological activities. Sheng et al. [54] attached the hydrogen sulfide donors to oleanolic acid, ursolic acid, and glycyrrhetinic acid to afford series of pentacyclic triterpenes-H2S donor hybrids (Figure 20). The anti-proliferation activity of these hybrids on the tested cell lines was evaluated by MTTassay. The results showed that most of these pentacyclic triterpenes-H2S donor hybrids exhibited no anti-proliferation activity against tested cell lines. Therefore, it is not suitable to hybridize hydrogen sulfide donors with oleanolic acid, ursolic acid, and glycyrrhetinic acid in anti-tumor applications.

3. Conclusions

As an endogenous gas signaling molecule, H2S has been shown to have a variety of biological effects. Decreased levels of H2S in the body are closely associated with the development and progression of many diseases, therefore, using H2S donors to increase the internal H2S concentration has important pharmacological significance. In recent years, research on ADTOH has been on the rise, and H2S donors represented by ADTOH are often used to synthesize novel ‘conjugate’ compounds that can release H2S and parent drugs. This design conforms to the idea of ‘multi-mechanism drugs’.
As a gas molecule, the activity of H2S is closely related to its release site, concentration and velocity. Although ADTOH is frequently used for the design and synthesis of H2S donor drugs, its selectivity of H2S-release still needs to be improved. In addition, how to design a long-acting, slow-controlled release of H2S from ADTOH conjugate drugs, and ensure it releases appropriate H2S concentrations at the target site is another key issue in the development of conjugate drugs. This review summarizes the hybrid compounds of ADTOH and parent drugs in order to provide a reference for the study of ADTOH-based donor drug design.

Author Contributions

Conceptualization, Y.M. and S.W.; methodology, Y.M. and S.W.; formal analysis, S.W. and Y.W.; investigation, S.W. and W.Y.; resources, S.W., W.Y. and J.G.; data curation, C.C., W.Y. and J.G.; writing—original draft preparation, S.W., C.C., W.Y., J.G. and Y.W.; writing—review and editing, S.W., C.C., W.Y., J.G. and Y.M.; supervision, Y.M. and S.W. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by Projects 81703363 of the National Natural Science Foundation of China; Six Talent Peaks Project in Jiangsu Province (YY-110); the Natural Science Fund for colleges and universities in Jiangsu Province (21KJB350008); 333 High Level Talent Training Project; Science and Technology Support Program (Social Development) of Taizhou (TN202135).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data have been included in the manuscript.

Acknowledgments

We thank Yi Mou for her support of this study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Vandiver, M.; Snyder, S.H. Hydrogen sulfide: A gasotransmitter of clinical relevance. J. Mol. Med. 2012, 90, 255–263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Wang, R. Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol. Rev. 2012, 92, 791–896. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Kolluru, G.K.; Shen, X.; Bir, S.C.; Kevil, C.G. Hydrogen sulfide chemical biology: Pathophysiological roles and detection. Nitric Oxide 2013, 35, 5–20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Martelli, A.; Testai, L.; Breschi, M.C.; Blandizzi, C.; Virdis, A.; Taddei, S.; Calderone, V. Hydrogen sulphide: Novel opportunity for drug discovery. Med. Res. Rev. 2012, 32, 1093–1130. [Google Scholar] [CrossRef]
  5. Zanardo, R.C.; Brancaleone, V.; Distrutti, E.; Fiorucci, S.; Cirino, G.; Wallace, J.L. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006, 20, 2118–2120. [Google Scholar] [CrossRef]
  6. Yonezawa, D.; Sekiguchi, F.; Miyamoto, M.; Taniguchi, E.; Honjo, M.; Masuko, T.; Nishikawa, H.; Kawabata, A. A protective role of hydrogen sulfide against oxidative stress in rat gastric mucosal epithelium. Toxicology 2007, 241, 11–18. [Google Scholar] [CrossRef]
  7. Laggner, H.; Hermann, M.; Esterbauer, H.; Muellner, M.K.; Exner, M.; Gmeiner, B.M.; Kapiotis, S. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells. J. Hypertens. 2007, 25, 2100–2104. [Google Scholar] [CrossRef]
  8. Sivarajah, A.; Collino, M.; Yasin, M.; Benetti, E.; Gallicchio, M.; Mazzon, E.; Cuzzocrea, S.; Fantozzi, R.; Thiemermann, C. Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock 2009, 31, 267–274. [Google Scholar] [CrossRef]
  9. Zhang, H.; Huang, Y.; Chen, S.; Tang, C.; Wang, G.; Du, J.; Jin, H. Hydrogen sulfide regulates insulin secretion and insulin resistance in diabetes mellitus, a new promising target for diabetes mellitus treatment? A review. J. Adv. Res. 2021, 27, 19–30. [Google Scholar] [CrossRef]
  10. Filipovic, M.R.; Zivanovic, J.; Alvarez, B.; Banerjee, R. Chemical Biology of H2S Signaling through Persulfidation. Chem. Rev. 2018, 118, 1253–1337. [Google Scholar] [CrossRef]
  11. Magli, E.; Perissutti, E.; Santagada, V.; Caliendo, G.; Corvino, A.; Esposito, G.; Esposito, G.; Fiorino, F.; Migliaccio, M.; Scognamiglio, A.; et al. H2S Donors and Their Use in Medicinal Chemistry. Biomolecules 2021, 11, 1899. [Google Scholar] [CrossRef] [PubMed]
  12. Li, L.; Whiteman, M.; Guan, Y.Y.; Neo, K.L.; Cheng, Y.; Lee, S.W.; Zhao, Y.; Baskar, R.; Tan, C.H.; Moore, P.K. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): New insights into the biology of hydrogen sulfide. Circulation 2008, 117, 2351–2360. [Google Scholar] [CrossRef] [Green Version]
  13. Martelli, A.; Testai, L.; Citi, V.; Marino, A.; Pugliesi, I.; Barresi, E.; Nesi, G.; Rapposelli, S.; Taliani, S.; Da Settimo, F.; et al. Arylthioamides as H2S Donors: L-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo. ACS Med. Chem. Lett. 2013, 4, 904–908. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Lee, M.; Tazzari, V.; Giustarini, D.; Rossi, R.; Sparatore, A.; Del Soldato, P.; McGeer, E.; McGeer, P.L. Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: Potential for treating Parkinson disease. J. Biol. Chem. 2010, 285, 17318–17328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Powell, C.R.; Dillon, K.M.; Matson, J.B. A review of hydrogen sulfide (H2S) donors: Chemistry and potential therapeutic applications. Biochem. Pharmacol. 2018, 149, 110–123. [Google Scholar] [CrossRef]
  16. Zhao, Y.; Yang, C.; Organ, C.; Li, Z.; Bhushan, S.; Otsuka, H.; Pacheco, A.; Kang, J.; Aguilar, H.C.; Lefer, D.J.; et al. Design, Synthesis, and Cardioprotective Effects of N-Mercapto-Based Hydrogen Sulfide Donors. J. Med. Chem. 2015, 58, 7501–7511. [Google Scholar] [CrossRef]
  17. Caliendo, G.; Cirino, G.; Santagada, V.; Wallace, J.L. Synthesis and biological effects of hydrogen sulfide (H2S): Development of H2S-releasing drugs as pharmaceuticals. J. Med. Chem. 2010, 53, 6275–6286. [Google Scholar] [CrossRef]
  18. Bindu, S.; Mazumder, S.; Bandyopadhyay, U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol. 2020, 180, 114147. [Google Scholar] [CrossRef]
  19. Schjerning, A.M.; McGettigan, P.; Gislason, G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat. Rev. Cardiol. 2020, 17, 574–584. [Google Scholar] [CrossRef]
  20. Chattopadhyay, M.; Kodela, R.; Nath, N.; Barsegian, A.; Boring, D.; Kashfi, K. Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem. Pharmacol. 2012, 83, 723–732. [Google Scholar] [CrossRef]
  21. Chattopadhyay, M.; Nath, N.; Kodela, R.; Sobocki, T.; Metkar, S.; Gan, Z.Y.; Kashfi, K. Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Leuk Res. 2013, 37, 1302–1308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Distrutti, E.; Sediari, L.; Mencarelli, A.; Renga, B.; Orlandi, S.; Russo, G.; Caliendo, G.; Santagada, V.; Cirino, G.; Wallace, J.L.; et al. 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J. Pharmacol. Exp. Ther. 2006, 319, 447–458. [Google Scholar] [CrossRef] [Green Version]
  23. Wang, C.; Xia, G.; Liu, X.; Zhang, R.; Chai, Y.; Zhang, J.; Li, X.; Yang, Y.; Wang, J.; Liu, M. Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. Bioorg. Med. Chem. Lett. 2016, 26, 2355–2359. [Google Scholar] [CrossRef] [PubMed]
  24. Wallace, J.L.; Caliendo, G.; Santagada, V.; Cirino, G.; Fiorucci, S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007, 132, 261–271. [Google Scholar] [CrossRef]
  25. Rossoni, G.; Sparatore, A.; Tazzari, V.; Manfredi, B.; Del Soldato, P.; Berti, F. The hydrogen sulphide-releasing derivative of diclofenac protects against ischaemia-reperfusion injury in the isolated rabbit heart. Br. J. Pharmacol. 2008, 153, 100–109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Gemici, B.; Elsheikh, W.; Feitosa, K.B.; Costa, S.K.; Muscara, M.N.; Wallace, J.L. H2S-releasing drugs: Anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide 2015, 46, 25–31. [Google Scholar] [CrossRef]
  27. Kodela, R.; Chattopadhyay, M.; Kashfi, K. Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential. Med. Chem. Comm. 2013, 4, 1472–1481. [Google Scholar] [CrossRef] [Green Version]
  28. Kashfi, K.; Chattopadhyay, M.; Kodela, R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 2015, 6, 287–296. [Google Scholar] [CrossRef] [Green Version]
  29. Tao, T.; Liu, M.; Chen, M.; Luo, Y.; Wang, C.; Xu, T.; Jiang, Y.; Guo, Y.; Zhang, J.H. Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective. Pharmacol. Ther. 2020, 216, 107695. [Google Scholar] [CrossRef]
  30. Jia, J.; Li, J.; Cheng, J. H(2)S-based therapies for ischaemic stroke: Opportunities and challenges. Stroke Vasc. Neurol. 2019, 4, 63–66. [Google Scholar] [CrossRef]
  31. Chen, X.Q.; Qiu, K.; Liu, H.; He, Q.; Bai, J.H.; Lu, W. Application and prospects of butylphthalide for the treatment of neurologic diseases. Chin. Med. J. 2019, 132, 1467–1477. [Google Scholar] [CrossRef] [PubMed]
  32. Wang, S.; Ma, F.; Huang, L.; Zhang, Y.; Peng, Y.; Xing, C.; Feng, Y.; Wang, X.; Peng, Y. Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol. Disord. Drug Targets 2018, 17, 338–347. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, X.; Wang, L.; Sheng, X.; Huang, Z.; Li, T.; Zhang, M.; Xu, J.; Ji, H.; Yin, J.; Zhang, Y. Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents. Org. Biomol. Chem. 2014, 12, 5995–6004. [Google Scholar] [CrossRef]
  34. Wang, X.; Wang, Z.; Wang, L.; Ji, H.; Zhang, Y.; Yin, J. Design, synthesis and evaluation of hydrogen sulfide-releasing derivatives of ring opening 3-n-butylphthalide as novel platelet aggregation inhibitors. J. China Pharm. Univ. 2016, 47, 158–162. [Google Scholar]
  35. Yin, W.; Lan, L.; Huang, Z.; Ji, J.; Fang, J.; Wang, X.; Ji, H.; Peng, S.; Xu, J.; Zhang, Y. Discovery of a ring-opened derivative of 3-n-butylphthalide bearing NO/H2S-donating moieties as a potential anti-ischemic stroke agent. Eur. J. Med. Chem. 2016, 115, 369–380. [Google Scholar] [CrossRef]
  36. Wang, X.-L.; Wang, Z.-Y.; Ling, J.-J.; Zhang, Y.-H.; Yin, J. Synthesis and biological evaluation of nitric oxide (NO)-hydrogen sulfide (H2S) releasing derivatives of (S)-3- n -butylphthalide as potential antiplatelet agents. Chin. J. Nat. Med. 2016, 14, 946–953. [Google Scholar] [CrossRef]
  37. Kothawade, P.B.; Thomas, A.B.; Chitlange, S.S. Novel Niacin Receptor Agonists: A Promising Strategy for the Treatment of Dyslipidemia. Mini Rev. Med. Chem. 2021, 21, 2481–2496. [Google Scholar] [CrossRef]
  38. Sakakibara, Y.; Mitha, A.P.; Ogilvy, C.S.; Maynard, K.I. Post-treatment with nicotinamide (vitamin B(3)) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague-Dawley and Wistar rats. Neurosci. Lett. 2000, 281, 111–114. [Google Scholar] [CrossRef]
  39. Sun, Y.; Zhang, Y.; Li, Y.; Cheng, J.; Chen, S.; Xiao, Y.; Ao, G. Synthesis and biological evaluation of novel hydrogen sulfide releasing nicotinic acid derivatives. Bioorg. Med. Chem. 2016, 24, 5368–5373. [Google Scholar] [CrossRef] [PubMed]
  40. Liu, Y.Y.; Sparatore, A.; Del Soldato, P.; Bian, J.S. ACS84, a novel hydrogen sulfide-releasing compound, protects against amyloid beta-induced cell cytotoxicity. Neurochem. Int. 2011, 58, 591–598. [Google Scholar] [CrossRef]
  41. Chegaev, K.; Rolando, B.; Cortese, D.; Gazzano, E.; Buondonno, I.; Lazzarato, L.; Fanelli, M.; Hattinger, C.M.; Serra, M.; Riganti, C.; et al. H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. J. Med. Chem. 2016, 59, 4881–4889. [Google Scholar] [CrossRef] [PubMed]
  42. Perrino, E.; Uliva, C.; Lanzi, C.; Soldato, P.D.; Masini, E.; Sparatore, A. New prostaglandin derivative for glaucoma treatment. Bioorg. Med. Chem. Lett. 2009, 19, 1639–1642. [Google Scholar] [CrossRef] [PubMed]
  43. Osborne, N.N.; Ji, D.; Abdul Majid, A.S.; Fawcett, R.J.; Sparatore, A.; Del Soldato, P. ACS67, a hydrogen sulfide-releasing derivative of latanoprost acid, attenuates retinal ischemia and oxidative stress to RGC-5 cells in culture. Investig. Ophthalmol. Vis. Sci. 2010, 51, 284–294. [Google Scholar] [CrossRef] [PubMed]
  44. Tang, G.; Zhang, L.; Yang, G.; Wu, L.; Wang, R. Hydrogen sulfide-induced inhibition of L-type Ca2+ channels and insulin secretion in mouse pancreatic beta cells. Diabetologia 2013, 56, 533–541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Braga, T.C.; de Jesus, I.C.G.; Soares, K.V.; Guatimosim, S.; da Silva Neto, L.; da-Silva, C.J.; Modolo, L.V.; Menezes Filho, J.E.R.; Rhana, P.; Cruz, J.S.; et al. A novel H2S releasing-monastrol hybrid (MADTOH) inhibits L-type calcium channels. New J. Chem. 2021, 45, 671–678. [Google Scholar] [CrossRef]
  46. Ou, X.; Xia, T.; Yang, C.; Yu, C.; Zhang, S.; Huang, R.; Chen, C.; Zhou, C. Novel H2S donor proglumide-ADT-OH protects HUVECs from ox-LDL-induced injury through NF-kappaB and JAK/SATA pathway. Open Med. (Wars) 2021, 16, 1318–1327. [Google Scholar] [CrossRef]
  47. Shukla, N.; Rossoni, G.; Hotston, M.; Sparatore, A.; Del Soldato, P.; Tazzari, V.; Persad, R.; Angelini, G.D.; Jeremy, J.Y. Effect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats. BJU Int. 2009, 103, 1522–1529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. d’Emmanuele di Villa Bianca, R.; Sorrentino, R.; Maffia, P.; Mirone, V.; Imbimbo, C.; Fusco, F.; De Palma, R.; Ignarro, L.J.; Cirino, G. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc. Natl. Acad. Sci. USA 2009, 106, 4513–4518. [Google Scholar] [CrossRef] [Green Version]
  49. Tang, X.Q.; Chen, R.Q.; Dong, L.; Ren, Y.K.; Del Soldato, P.; Sparatore, A.; Liao, D.F. Role of Paraoxonase-1 in the Protection of Hydrogen Sulfide-Donating Sildenafil (ACS6) Against Homocysteine-Induced Neurotoxicity. J. Mol. Neurosci. 2013, 50, 70–77. [Google Scholar] [CrossRef]
  50. Giordano, F.; Corvino, A.; Scognamiglio, A.; Citi, V.; Gorica, E.; Fattorusso, C.; Persico, M.; Caliendo, G.; Fiorino, F.; Magli, E.; et al. Hybrids between H2S-donors and betamethasone 17-valerate or triamcinolone acetonide inhibit mast cell degranulation and promote hyperpolarization of bronchial smooth muscle cells. Eur. J. Med. Chem. 2021, 221, 113517. [Google Scholar] [CrossRef]
  51. Corvino, A.; Citi, V.; Fiorino, F.; Frecentese, F.; Magli, E.; Perissutti, E.; Santagada, V.; Calderone, V.; Martelli, A.; Gorica, E.; et al. H2S donating corticosteroids: Design, synthesis and biological evaluation in a murine model of asthma. J. Adv. Res. 2022, 35, 267–277. [Google Scholar] [CrossRef] [PubMed]
  52. Del Soldato, P.; Santus, G. Ophthalmic Pharmaceutical Compositions. WO2009109501A2 [P], 22 May 2009. [Google Scholar]
  53. Tong, J.; Shen, X.; Ju, C. Atorvastatin Derivative, Pharmaceutical Composition and Pharmaceutical Applications Thereof. CN103113360A [P], 19 February 2013. [Google Scholar]
  54. Sheng, L.-X.; Huang, J.-Y.; Liu, C.-M.; Zhang, J.-Z.; Cheng, K.-G. Synthesis of oleanolic acid/ursolic acid/glycyrrhetinic acid-hydrogen sulfide donor hybrids and their antitumor activity. Med. Chem. Res. 2019, 28, 1212–1222. [Google Scholar] [CrossRef]
Molecules 28 00331 g001 550
Figure 1. Structures of representative synthetic H2S donors.
Figure 1. Structures of representative synthetic H2S donors.
Molecules 28 00331 g001
Molecules 28 00331 g002 550
Figure 2. Mechanism of H2S release from ADTOH.
Figure 2. Mechanism of H2S release from ADTOH.
Molecules 28 00331 g002
Molecules 28 00331 g003 550
Figure 3. Structures of NOSH-aspirin and HS-aspirin.
Figure 3. Structures of NOSH-aspirin and HS-aspirin.
Molecules 28 00331 g003
Molecules 28 00331 g004 550
Figure 4. Structures of ATB-429 and compound 1a, 1b.
Figure 4. Structures of ATB-429 and compound 1a, 1b.
Molecules 28 00331 g004
Molecules 28 00331 g005 550
Figure 5. Structures of ACS15 and ATB-352.
Figure 5. Structures of ACS15 and ATB-352.
Molecules 28 00331 g005
Molecules 28 00331 g006 550
Figure 6. Structures of AVT-219 and AVT-18A.
Figure 6. Structures of AVT-219 and AVT-18A.
Molecules 28 00331 g006
Molecules 28 00331 g007a 550Molecules 28 00331 g007b 550
Figure 7. Structures of ADTOH–NBP conjugates.
Figure 7. Structures of ADTOH–NBP conjugates.
Molecules 28 00331 g007aMolecules 28 00331 g007b
Molecules 28 00331 g008 550
Figure 8. Structures of NOSH–NBP conjugates.
Figure 8. Structures of NOSH–NBP conjugates.
Molecules 28 00331 g008
Molecules 28 00331 g009 550
Figure 9. Structures of ADTOH–niacin conjugates.
Figure 9. Structures of ADTOH–niacin conjugates.
Molecules 28 00331 g009
Molecules 28 00331 g010 550
Figure 10. Structures of ADTOH–levodopa conjugates.
Figure 10. Structures of ADTOH–levodopa conjugates.
Molecules 28 00331 g010
Molecules 28 00331 g011 550
Figure 11. Structures of ADTOH–doxorubicin conjugates.
Figure 11. Structures of ADTOH–doxorubicin conjugates.
Molecules 28 00331 g011
Molecules 28 00331 g012 550
Figure 12. Structure of ACS67.
Figure 12. Structure of ACS67.
Molecules 28 00331 g012
Molecules 28 00331 g013 550
Figure 13. Structure of MADTOH.
Figure 13. Structure of MADTOH.
Molecules 28 00331 g013
Molecules 28 00331 g014 550
Figure 14. Structure of PA.
Figure 14. Structure of PA.
Molecules 28 00331 g014
Molecules 28 00331 g015 550
Figure 15. Structure of ACS6.
Figure 15. Structure of ACS6.
Molecules 28 00331 g015
Molecules 28 00331 g016 550
Figure 16. Structures of betamethasone and triamcinolone conjugates.
Figure 16. Structures of betamethasone and triamcinolone conjugates.
Molecules 28 00331 g016
Molecules 28 00331 g017 550
Figure 17. Structures of prednisone and dexamethasone conjugates.
Figure 17. Structures of prednisone and dexamethasone conjugates.
Molecules 28 00331 g017
Molecules 28 00331 g018 550
Figure 18. Structure of compound 8.
Figure 18. Structure of compound 8.
Molecules 28 00331 g018
Molecules 28 00331 g019 550
Figure 19. Structures of ADTOH–atorvastatin conjugates.
Figure 19. Structures of ADTOH–atorvastatin conjugates.
Molecules 28 00331 g019
Molecules 28 00331 g020 550
Figure 20. Structures of ADTOH–pentacyclic triterpene conjugates.
Figure 20. Structures of ADTOH–pentacyclic triterpene conjugates.
Molecules 28 00331 g020
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wen, S.; Cao, C.; Ge, J.; Yang, W.; Wang, Y.; Mou, Y. Research Progress of H2S Donors Conjugate Drugs Based on ADTOH. Molecules 2023, 28, 331. https://doi.org/10.3390/molecules28010331

AMA Style

Wen S, Cao C, Ge J, Yang W, Wang Y, Mou Y. Research Progress of H2S Donors Conjugate Drugs Based on ADTOH. Molecules. 2023; 28(1):331. https://doi.org/10.3390/molecules28010331

Chicago/Turabian Style

Wen, Shuai, Changchang Cao, Jianwen Ge, Wenzhe Yang, Yan Wang, and Yi Mou. 2023. "Research Progress of H2S Donors Conjugate Drugs Based on ADTOH" Molecules 28, no. 1: 331. https://doi.org/10.3390/molecules28010331

APA Style

Wen, S., Cao, C., Ge, J., Yang, W., Wang, Y., & Mou, Y. (2023). Research Progress of H2S Donors Conjugate Drugs Based on ADTOH. Molecules, 28(1), 331. https://doi.org/10.3390/molecules28010331

Article Metrics

Back to TopTop